FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Immunotherapy topics
Immunotherapy
Therapeutics
Antibodies
Immune Response
Monoclonal
Monoclonal Antibody
Stimulator
Immunostimulator
Compatibility
Histocompatibility
Specificity
Major Histocompatibility Complex
Radiation Therapy
Treatments
Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immunotherapy patents



      
           
This page is updated frequently with new Immunotherapy-related patent applications. Subscribe to the Immunotherapy RSS feed to automatically get the update: related Immunotherapy RSS feeds. RSS updates for this page: Immunotherapy RSS RSS


Date/App# patent app List of recent Immunotherapy-related patents
08/07/14
20140220605
 Vmp-like sequences of pathogenic borrelia species and strains patent thumbnailVmp-like sequences of pathogenic borrelia species and strains
The present invention relates to dna sequences encoding vmp-like polypeptides of pathogenic borrelia, the use of the dna sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the dna and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, dna segments and antibodies..
08/07/14
20140220562
 Method of predicting responsiveness of b cell lineage malignancies to active immunotherapy patent thumbnailMethod of predicting responsiveness of b cell lineage malignancies to active immunotherapy
Predictive biomarkers identify those patients suffering from immunoglobulin positive (ig+) b lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the cdr1 (herein termed cdr1-y10) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of cdr1 tyrosine residues (herein termed cdr1-yhi) is predictive of a low anti tumor response..
08/07/14
20140220011
 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics patent thumbnailPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, clorf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
08/07/14
20140219914
 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity patent thumbnailDosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
07/31/14
20140212422
 Methods for treating cancer using anti-pd-1 antibodies in combination with anti-ctla-4 antibodies patent thumbnailMethods for treating cancer using anti-pd-1 antibodies in combination with anti-ctla-4 antibodies
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
07/24/14
20140206724
 Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent patent thumbnailMethods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
07/24/14
20140206723
 Methods for treating amyloidosis with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione patent thumbnailMethods for treating amyloidosis with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
07/24/14
20140206654
 Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ patent thumbnailUse of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ
The present invention refers to the use of a compound of formula (i′) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodysplastic syndromes (mdss) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a compound of formula (i″) for the treatment and/or prophylaxis of cancer of an organ..
07/24/14
20140205680
 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer patent thumbnailMethods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid.
07/17/14
20140199344
 Anti-measles cancer immunotherapy patent thumbnailAnti-measles cancer immunotherapy
The present invention provides methods for treating specific populations of cancer patients by immunotherapy. The methods comprise administering an immunogenic composition eliciting an immune response to measles virus to patients having measles virus-immunoreactive cancer cells..
07/17/14
20140199336
Tmem22 peptides and vaccines including the same
Isolated peptides composed of the amino acid sequence of seq id no: 33 or fragments thereof that bind to hla antigens and have cytotoxic t lymphocyte (ctl) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic t cell inducibility.
07/17/14
20140199298
Combination treatment of cancer comprising egfr/her2 inhibitors
Optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.. .
07/10/14
20140193444
Allergen peptide fragments and use thereof for treatment of dust mite allergies
The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which together form an entire amino acid sequence of an allergen..
07/10/14
20140193417
Membrane transporter napi2b (scl34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
The present disclosure relates generally to the membrane transporter napi2b (slc34a2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The slc34a2 epitope peptide encompassing amino acids 312-340 of slc34a2 has been identified as an ovarian cancer epitope using the monoclonal antibody mx35.
07/03/14
20140186404
Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in combination with antibodies
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
07/03/14
20140186401
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
In one embodiment, a single modality cancer immunotherapy regimen that includes a therapeutic composition is provided. Such a therapeutic composition may include a salmonella strain comprising a plasmid that expresses an shrna molecule that suppresses the expression of an immunosuppressive target and suppresses tumor growth.
07/03/14
20140186380
Immunotherapy with binding agents
Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies.
07/03/14
20140186374
Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
We demonstrate herein that neuritin controls the homeostasis of regulatory t cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory t cells in various disease settings is described.
06/26/14
20140179004
Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
A cell of the present invention contains a nucleic acid construct encoding a wt1 gene product or a fragment of the wt1 gene product. The nucleic acid construct contains (i) a region encoding a desired fragment of the wt1 gene product and (ii) only aug as a functional start codon.
06/26/14
20140178968
Genetic variant of cytomegalovirus (cmv)
The present invention relates to a genetic variant of cmv, said genetic variant lacking intron 2 of the ie region of cmv (cmv ieΔi2) the present invention also relates to various uses of this genetic variant as well as rna splice variants transcribed therefrom, and proteins expressed from the rna splice variants, such as in the diagnosis of a cmv related cancer disease, and identification of individuals at risk of developing cancer or risk of transferring the cmv ieΔi2 virus with a human sample and prevention and treatment through targeting of unique cmv ie proteins for immunotherapy and vaccination.. .
06/26/14
20140178906
Monoclonal antibodies against pcbp-1 antigens, and uses therefor
The present invention provides and includes monoclonal antibodies specific or preferentially selective for pcbp-1 antigens, hybridoma lines that secrete these pcbp-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect pcbp-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of pcbp-1.
06/26/14
20140178438
Individualized vaccines for cancer
The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a).
06/26/14
20140178409
Sema5b peptides and vaccines including the same
As discussed in detail herein, isolated epitope peptides derived from sema5b bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite hla binding and/or ctl inducibility of the original sequences.
06/26/14
20140178334
Methods and compositions for liquidation of tumors
This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors whereever they reside in the body.
06/19/14
20140170225
Immunotherapy for treatment of amyloid-related disorders using encapsulated beta-amyloid peptides
The present invention relates to the field of polymer chemistry and more particularly to encapsulated peptides and uses thereof.. .
06/19/14
20140170063
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 rop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
06/12/14
20140161806
Immunogenic synthetic glycoconjugate for the immunotherapy of melanoma
Wherein x is o, nh, s, ch2; l is a linker that is a divalent spacer; a is an adjuvant or carrier that is an immunogenic molecule or an immunogenic particle; and wherein bonds between linker and saccharide moiety and between linker and carrier are of covalent type; wherein the linker l presents a chemical structure suitable to space the saccharide moiety and the carrier by 7-30 atoms when the adjuvant/carrier a is a biomacromolecule or by 19-30 atoms when the adjuvant/carrier a is a metallic nanoparticle; wherein the carrier/adjuvant a can be selected among a macromolecule, a macrocycle, a dendrimer, a liposome, a nanoparticle, an oligosaccharide featuring from two to five monosaccharidic units or cells like dendritic cells.. .
06/12/14
20140161773
Use of an agent that restores tissue perfusion and oxygenation
The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects.
06/05/14
20140154281
Mphosph1 peptides and vaccines including the same
As discussed in greater detail herein, isolated epitope peptides derived from mphosph1 bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned mphosph1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite ctl inducibility of the original sequences.
05/29/14
20140147470
Methods of predicting host responsiveness to cancer immunotherapies by ex vivo induction of leukocyte-function-associated mrnas
Embodiments of the invention relate generally to ex vivo methods of quantifying expression of leukocyte-function associated mrnas and using the quantification to characterize an individual's potential responsiveness to cancer immunotherapy. Certain embodiments relate to methods to monitor the efficacy of ongoing cancer immunotherapy by evaluating expression of leukocyte-function associated mrnas genes before and administration of an anti-cancer immunotherapy regimen..
05/29/14
20140147411
Methods of treating cancer and testing mutation zygosity related thereto
In certain embodiments, the disclosure relates to methods of treating cancer comprising administering an effective amount a tyrosine kinase inhibitor in combination with an immunotherapy to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating cancer comprising: i) analyzing both chromosomes in a cell from a subject for the a v600e mutation of braf; and ii) determining if both of the chromosomes contain the v600e mutation, then treating the subject comprising the step of administering an effective amount a tyrosine kinase inhibitor in combination with an immunotherapy to the subject..
05/29/14
20140147382
Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
The invention is directed to a method for treating a treating and diagnosing a b cell-related disease, t cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed.. .
05/22/14
20140141045
Allogeneic tumor cell vaccination
The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions.
05/22/14
20140141039
Biomarker for monitoring patients
The present invention is in the field of immunotherapy and relates to methods for determining the efficacy of certain immunotherapy treatments. The methods of the invention include measuring special biomarker at some time following the initiation of immunotherapy treatment to evaluate the clinical outcome of the said treatment.
05/15/14
20140134142
Multi-chain chimeric antigen receptor and uses thereof
The present invention relates to a new generation of chimeric antigen receptors (car) referred to as multi-chain cars. Such cars, which aim to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties, comprise separate extracellular ligand binding and signaling domains in different transmembrane polypeptides.
05/08/14
20140127298
Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
The present invention relates to mucosal allergen-specific immunotherapy with a seasonal allergen, wherein the therapy is initiated after start of the pollen season of the seasonal allergen. Preferably, the seasonal allergen is provided in solid dosage form and is administered daily.
05/08/14
20140127242
Novel and powerful mhc-class ii peptides derived from survivin
The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic t cell (ctl) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses.
05/01/14
20140120072
Method for amplifying nk cells
A method for amplifying nk cells is provided which comprises steps of: preparing cell population which is comprised of nk cells, removing t cells from the cell population which is comprised of nk cells, and, after removal of t cells, cultivating the remaining cells in a medium supplemented with 2500 to 2831 iu/ml of il-2. The method for amplifying nk cells of the present invention may comprise a step of removing hematopoietic progenitor cells from the cell population.
04/24/14
20140112955
Biomarkers of immunotherapy efficacy
The invention relates to proteins for use as a marker for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy.
04/24/14
20140112920
Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as revlimid® or lenalidomide.
04/17/14
20140108050
Xtract preparation system and method
Embodiments of the invention relate to performing a method for point of care treatment of a patient for safe effective generation of immunotherapy patient treatment sets. The method includes receiving a command to formulate a prescription; loading contents of each door; receiving a command to load physician preferences; loading physician preferences; receiving a command to load patient information; making prescription per patient information in accordance with physician preferences; printing and applying labels to prescription; and documenting a plurality of clinical activities..
04/17/14
20140105923
Tumor antigen proteins or genes of polo-like kinase 1
The present invention relates to tumor antigen proteins or genes derived from polo-like kinase 1. As a result of the formation of a complex by binding polo-like kinase 1-derived proteins or variants having characteristics functionally identical to the proteins with mhc class i antigens or ii antigens, the complex can be recognized by cytotoxic t lymphocytes.
04/17/14
20140105906
Peptide for protection of allergic respiratory disorders
A peptide (peptide-1) based on the c-terminal of equine cc10 has been discovered that can be used as a vaccine to protect horses from respiratory airway obstruction (rao). Antibodies to peptide-1 may also be administered for short-term passive immunotherapy to rao-affected horses, and can be used to measure the level of cc10 protein in serum to identify potential rao horses (horses with reduced cc10).
04/10/14
20140099305
Compositions and methods for cancer immunotherapy
Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a liver-expressed chemokine (lec). In one embodiment, the cancer targeting molecule is an antibody that targets cancer cells or tumors in vivo.
04/03/14
20140093541
Treatment for peanut allergy
The present invention relates to oral immunotherapy for the desensitisation of patients who are hypersensitive to peanut allergen. The immunotherapy comprises increasing the oral dose daily dose of peanut protein administered to the patient at intervals of at least 2 weeks in a series of increments from an initial dose to a maximum dose, the series of dose increments including 2 mg, 5 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg and 800 mg; administering a daily oral dose of the maximum dose of peanut protein for at least 2 years and then administering a weekly oral dose of the maximum dose of peanut protein for at least 2 years..
03/27/14
20140086957
Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells
Disclosed are pharmaceutical compositions for inducing an immune response against tumor cells comprising tumor cells which are made apoptotic by treatment with high hydrostatic pressure and dendritic cells, and methods for producing such compositions.. .
03/27/14
20140086943
Novel and powerful mhc-class ii peptides derived from survivin
The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic t cell (ctl) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses.
03/27/14
20140086932
Method for enhancing specific immunotherapies in cancer treatment
Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer..
03/27/14
20140086829
Recombinant antibodies to the vascular endothelial growth factor (vegf) which are obtained by means of mutagenesis of variable regions
The present invention reveals human recombinant antibodies that recognize the human vascular endothelium growth factor a (vegf-a), block its interaction with the vegfr2 receptor, and interfere with its proliferative effect in vitro and pro-angiogenic effect in vivo. The antibodies identify an epitope on human vegf-a different from any other previously reported, and were obtained by combining one immunoglobulin light chain variable region with other three heavy chain ones.
03/20/14
20140079706
Combination therapy of antibodies against human csf-1r and uses thereof
The present invention relates to the combination therapy of antibodies binding to human csf-1r, characterized in binding to the (dimerization) domains d4 to d5 (seq id no: 85) of the extracellular domain of human csf-1r in combination with a chemotherapeutic agent, radiation, and/or cancer immunotherapy.. .
03/13/14
20140072593
Method for suppressing an immune response
The invention is in the field of molecular immunology, more in particular in the field of medical treatment of animals such as humans suffering from unwanted immune reactions. The invention relates to methods for the treatment of unwanted immune reactions and provides means and methods for suppressing an immune response.
03/13/14
20140072590
Compositions and methods for the treatment or prevention of human adenovirus-36 infection
Disclosed are fusion proteins, recombinant nucleic acid molecules, and therapeutic compositions, including yeast-based immunotherapy compositions, for use in the diagnosis, prevention and treatment of adenovirus-36 (ad-36) infection and sequela thereof.. .
03/13/14
20140072528
Immunotherapy
The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them..
03/06/14
20140065100
Compositions and methods for cancer immunotherapy
The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.. .
03/06/14
20140065097
Immunotherapy
The present invention provides combinations of (a) an immunoconjugate comprising at least one antigen-binding moiety and an effector moiety, and (b) an antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them..
03/06/14
20140065064
Monoclonal antibodies against alpha-actinin-4 antigens, and uses therefor
Monoclonal antibodies (moabs or mabs) specific for alpha-actinin-4 antigens, hybridoma lines that secrete these alpha-actinin-4 mabs, and the use of such mabs to detect alpha-actinin-4 antigens, particularly those expressed by cancer cells are disclosed. Chimeric and humanized antibodies based upon these anti-alpha-actinin-4 mabs, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant dna technology, and their therapeutic uses, particularly in the treatment of cancer are also disclosed.
02/27/14
20140056931
Genetic adjuvants for immunotherapy
The present invention pertains to methods and pharmaceutical compositions for modulating an immune response. The method of the present invention involves administration of an effective amount of nucleic acid molecules encoding interleukin-12 (il-12), interferon-gamma (ifn-γ), or a combination thereof, to a patient in need of such treatment.
02/27/14
20140056844
Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
Methods for treating cancer comprising administering a metabolic targeting chemo-immunotherapy regimen are provided herein. In one embodiment, the metabolic targeting chemo-immunotherapy regimen may include steps of administering a therapeutically effective dose of one or more immunologic agents (e.g., a therapeutic antibody) to stimulate an immune response in a subject having cancer; reducing the patient's blood glucose level; and administering a therapeutically effective dose of one or more chemotherapeutic agents.
02/20/14
20140050733
Apoe immunotherapy
The present invention provides antibodies that preferentially bind to an apoe(1-272) fragment relative to apoe(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases..


Popular terms: [SEARCH]

Immunotherapy topics: Immunotherapy, Therapeutics, Antibodies, Immune Response, Monoclonal, Monoclonal Antibody, Stimulator, Immunostimulator, Compatibility, Histocompatibility, Specificity, Major Histocompatibility Complex, Radiation Therapy, Treatments, Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immunotherapy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunotherapy with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



2.0367

3560

3 - 0 - 71